GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgalign Holdings Inc (OTCPK:SRGAQ) » Definitions » Altman Z-Score

Surgalign Holdings (Surgalign Holdings) Altman Z-Score : -13.54 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Surgalign Holdings Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -13.57 is in distress zone. This implies bankruptcy possibility in the next two years.

Surgalign Holdings has a Altman Z-Score of -13.54, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Surgalign Holdings's Altman Z-Score or its related term are showing as below:

SRGAQ' s Altman Z-Score Range Over the Past 10 Years
Min: -13.57   Med: 0.57   Max: 2.44
Current: -13.57

During the past 13 years, Surgalign Holdings's highest Altman Z-Score was 2.44. The lowest was -13.57. And the median was 0.57.


Surgalign Holdings Altman Z-Score Historical Data

The historical data trend for Surgalign Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgalign Holdings Altman Z-Score Chart

Surgalign Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -2.49 -8.42 -7.95 -13.25

Surgalign Holdings Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.61 -9.31 -11.43 -13.25 -13.56

Competitive Comparison of Surgalign Holdings's Altman Z-Score

For the Medical Devices subindustry, Surgalign Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgalign Holdings's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgalign Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Surgalign Holdings's Altman Z-Score falls into.



Surgalign Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Surgalign Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.4939+1.4*-9.1575+3.3*-0.7465+0.6*0.0019+1.0*1.1537
=-13.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2023:
Total Assets was $67.71 Mil.
Total Current Assets was $53.43 Mil.
Total Current Liabilities was $19.98 Mil.
Retained Earnings was $-620.07 Mil.
Pre-Tax Income was 4.278 + -40.446 + -9.795 + -5.596 = $-51.56 Mil.
Interest Expense was -0.252 + -0.253 + -0.252 + -0.252 = $-1.01 Mil.
Revenue was 16.748 + 20.573 + 20.178 + 20.623 = $78.12 Mil.
Market Cap (Today) was $0.17 Mil.
Total Liabilities was $86.65 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(53.43 - 19.984)/67.712
=0.4939

X2=Retained Earnings/Total Assets
=-620.073/67.712
=-9.1575

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-51.559 - -1.009)/67.712
=-0.7465

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.165/86.647
=0.0019

X5=Revenue/Total Assets
=78.122/67.712
=1.1537

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Surgalign Holdings has a Altman Z-Score of -13.54 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Surgalign Holdings  (OTCPK:SRGAQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Surgalign Holdings Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Surgalign Holdings's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgalign Holdings (Surgalign Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Lake Cook Road, Suite 315, Deerfield, IL, USA, 60015
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Executives
Elizabeth A. Lapuma director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Jill Kathleen Frizzley director P.O. BOX 1541, ONE BLUE HILL PLAZA, PEARL RIVER NY 10965
Paolo Amoruso officer: Chief Legal Officer C/O HYPERDYNAMICS CORPORATION, 12012 WICKCHESTER LANE, SUITE 475, HOUSTON TX 77079
David Lyle officer: Chief Financial Officer 6290 SEQUENCE DRIVE, SAN DIEGO CA 92121
Marc E. Mackey officer: EVP, Digital Surgery 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Terry M. Rich officer: President, Global Spine 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
William Scott Durall officer: Chief Commercial Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Christopher Thunander officer: Chief Accounting Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Thomas Mceachin director 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Enrico Sangiorgio officer: EVP, International 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Stuart F. Simpson director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Pawel Lewicki director 296 WOODWARD BLVD., TULSA OK 74114
Jeffrey C Lightcap director 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019